AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05936086
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
Trial: NCT05936086
Drug: Cyclosporine (CSA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
Trial: NCT00002187
Drug: Fomivirsen sodium
RxNorm normalized name: Fomivirsen Sodium
DrugBank: Fomivirsen (DB06759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02533115
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC.
Trial: NCT05755789
Drug: Loading bolus of cefoxitin
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoxitin \[2g\] before incision
Trial: NCT05755789
Drug: Intermittent cefoxitin
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
Trial: NCT05755789
Drug: Continuous infusion of cefoxitin
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
Trial: NCT04850950
Drug: Tenofovir Alafenamide fumarate 25mg Oral Tablet
RxNorm normalized name: tenofovir alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
Trial: NCT05690321
Drug: Opium tincture
RxNorm normalized name: opium tincture
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
Trial: NCT04722978
Drug: Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
Trial: NCT04722978
Drug: Gemcitabine combined with carboplatin plus placebo
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy (gemcitabine and carboplatin) plus placebo
Trial: NCT06356740
Drug: Treatment :Abacavir 600 mg/lamivudine 300 mg
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
Trial: NCT06295926
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
Trial: NCT04719585
Drug: Duloxetine vs. Opioid
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Trial: NCT05239091
Drug: Dextrose solution
RxNorm normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
Trial: NCT05239091
Drug: Lidocain
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
Trial: NCT05215574
Drug: NGM831 plus pembrolizumab (KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle.
Trial: NCT05215574
Drug: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle.
Trial: NCT05346302
Drug: Pneumovax 23
RxNorm normalized name: Pneumovax 23
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
Trial: NCT05346302
Drug: Typhim VI
RxNorm normalized name: Typhim VI
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
Trial: NCT05203965
Drug: Mavoglurant (AFQ056)
RxNorm normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.
Trial: NCT06320951
Drug: Vericiguat 10 MG
RxNorm normalized name: vericiguat 10 MG
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
Trial: NCT05277012
Drug: Etrumadenant
RxNorm normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrumadenant capsule and tablet formulations
Trial: NCT05714371
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receiving nivolumab
Trial: NCT05714371
Drug: Ipilimumab + nivolumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receiving ipilimumab + nivolumab
Trial: NCT05714371
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receiving pembrolizumab
Trial: NCT05714371
Drug: Dabrafenib + trametinib
RxNorm normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib + trametinib
Trial: NCT05437094
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole
Trial: NCT05631925
Drug: propofol bolus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be added in bolus doses of 0.5mg/kg.
Trial: NCT05631925
Drug: propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be administered as 10mg/kg/hour infusion.
Trial: NCT03723096
Drug: CC-4047
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-4047 will be administered orally
Trial: NCT06338644
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 weeks on, 1 week off
Trial: NCT04590612
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg tablet to be taken orally once and at the same time of the day, daily.
Trial: NCT05274438
Drug: JS001+Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered.
Trial: NCT00082082
Drug: Thymalfasin (thymosin alpha-1)
RxNorm normalized name: thymalfasin
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05568745
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose\*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
Trial: NCT05568745
Drug: Misoprostol Oral Tablet
RxNorm normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
Trial: NCT06187818
Drug: Crocin
RxNorm normalized name: CROCIN
DrugBank: Crocin (DB11874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
Trial: NCT06449625
Drug: Semaglutide Pen Injector [Ozempic]
RxNorm normalized name: semaglutide Pen Injector [Ozempic]
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide active drug
Trial: NCT04705480
Drug: Pregabalin 50mg
RxNorm normalized name: PREGABALIN 50MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
Trial: NCT04705480
Drug: Gabapentin 300mg
RxNorm normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
Trial: NCT04705480
Drug: Neither Pregabalin nor Gabapentin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive neither Pregabalin nor Gabapentin.
Trial: NCT04124367
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml once daily (+70 ml 0.9% saline)
Trial: NCT05702944
Drug: Phenoxybenzamine
RxNorm normalized name: Phenoxybenzamine
DrugBank: Phenoxybenzamine (DB00925)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
Trial: NCT05569577
Drug: estrogen and dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estrogen and dydrogesterone
Trial: NCT05475873
Drug: Ondansetron 4 mg
RxNorm normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
Trial: NCT05475873
Drug: Ondansetron 8 mg
RxNorm normalized name: ondansetron 8 MG
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
Trial: NCT06217406
Drug: Intravenous acyclovir (ACYCLOVIR )
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
Trial: NCT04831944
Drug: parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parsaclisib will be administered orally after 8 hours of fasting.
Trial: NCT05253807
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 13.5 mg tablet
Trial: NCT06332053
Drug: SY-5007
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
Trial: NCT06510426
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mL of saline administered subcutaneously
Trial: NCT05581719
Drug: Allocetra-OTS
RxNorm normalized name: Allocetra
DrugBank: Allocetra (DB16424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
Trial: NCT05581719
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)
Trial: NCT05581719
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)
Trial: NCT05418946
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment of T2D and cardio-renal prevention
Trial: NCT06332053
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg, Capsules, Day 8-Day 18
Trial: NCT06388369
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
Trial: NCT06332053
Drug: SY-5007
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
Trial: NCT06332053
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg, Capsules, Day 8-Day 21
Trial: NCT06143631
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral letrozole 2.5mg/day
Trial: NCT05128617
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 cycle of Paclitaxel
Trial: NCT04723537
Drug: Part A: Upamostat 200 mg
DrugBank: Upamostat (DB13052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
Trial: NCT04723537
Drug: Part A: Upamostat 400 mg
DrugBank: Upamostat (DB13052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules, each capsule comprising 200 mg of upamostat
Trial: NCT04723537
Drug: Part B: Upamostat 200 or 400 mg
DrugBank: Upamostat (DB13052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days.
Trial: NCT05027269
Drug: AOC 1001
RxNorm normalized name: AOC 1001
DrugBank: AOC 1001 (DB18620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOC 1001 will be administered by intravenous (IV) infusion.
Trial: NCT06498908
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
Trial: NCT06498908
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
Trial: NCT05965570
Drug: Brensocatib
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets.
Trial: NCT00002042
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06529497
Drug: Racecadotril
RxNorm normalized name: racecadotril
DrugBank: Racecadotril (DB11696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group will receive racecadotril+ORS+Zinc
Trial: NCT00029796
Drug: soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05983302
Drug: Platelet-Rich Plasma-Fibrin Glue
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
Trial: NCT05983302
Drug: Repairing Gel
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
Trial: NCT05983302
Drug: Repairing Gel and Platelet-Rich Plasma-Fibrin Glue
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
Trial: NCT04837040
Drug: Paltusotine
RxNorm normalized name: Paltusotine
DrugBank: Paltusotine (DB16277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paltusotine, tablets, once daily by mouth
Trial: NCT00002208
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002208
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002208
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002208
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no